Title |
CD40L and Its Receptors in Atherothrombosis—An Update
|
---|---|
Published in |
Frontiers in Cardiovascular Medicine, June 2017
|
DOI | 10.3389/fcvm.2017.00040 |
Pubmed ID | |
Authors |
Nathaly Anto Michel, Andreas Zirlik, Dennis Wolf |
Abstract |
CD40L (CD154), a member of the tumor necrosis factor superfamily, is a co-stimulatory molecule that was first discovered on activated T cells. Beyond its fundamental role in adaptive immunity-ligation of CD40L to its receptor CD40 is a prerequisite for B cell activation and antibody production-evidence from more than two decades has expanded our understanding of CD40L as a powerful modulator of inflammatory pathways. Although inhibition of CD40L with neutralizing antibodies has induced life-threatening side effects in clinical trials, the discovery of cell-specific effects and novel receptors with distinct functional consequences has opened a new path for therapies that specifically target detrimental properties of CD40L. Here, we carefully evaluate the signaling network of CD40L by gene enrichment analysis and its cell-specific expression, and thoroughly discuss its role in cardiovascular pathologies with a specific emphasis on atherosclerotic and thrombotic disease. |
X Demographics
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Geographical breakdown
Country | Count | As % |
---|---|---|
Switzerland | 2 | 50% |
Unknown | 2 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 75% |
Science communicators (journalists, bloggers, editors) | 1 | 25% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 63 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 9 | 14% |
Researcher | 6 | 10% |
Student > Bachelor | 5 | 8% |
Student > Ph. D. Student | 5 | 8% |
Student > Doctoral Student | 3 | 5% |
Other | 9 | 14% |
Unknown | 26 | 41% |
Readers by discipline | Count | As % |
---|---|---|
Immunology and Microbiology | 9 | 14% |
Biochemistry, Genetics and Molecular Biology | 9 | 14% |
Medicine and Dentistry | 6 | 10% |
Agricultural and Biological Sciences | 4 | 6% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
Other | 5 | 8% |
Unknown | 28 | 44% |